Article
Oncology
Arjun Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward M. Uchio, Joost L. Boormans, Mathieu Roumiguie, Laurence E. M. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Haojie Li, Kijoeng Nam, Ekta Kapadia, Tara Frenkl, Ronald de Wit
Summary: This study evaluated the efficacy and safety of pembrolizumab, a PD-1 inhibitor, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. The results showed that pembrolizumab monotherapy was well-tolerated and demonstrated promising antitumor activity in this patient population.
Article
Urology & Nephrology
Peter C. Black, Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance, Vadim S. Koshkin, Kelly L. Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson, Seth P. Lerner
Summary: This study evaluated the efficacy and safety of atezolizumab in BCG-unresponsive high-risk NMIBC patients who were ineligible for or declined surgery. The results showed that atezolizumab had a good pathological complete response rate in patients with carcinoma in situ, and some patients had durable responses. However, there were severe treatment-related adverse events in some patients.
Editorial Material
Urology & Nephrology
Divya A. Parikh, Ali Raza Kaki, Stephen B. Williams
Summary: The BRAVO study aimed to assess the feasibility of radical cystectomy (RC) and intravesical bacillus Calmette-Guerin (BCG) maintenance instillations in high-risk, high-grade non-muscle-invasive bladder cancer (HRNMIBC) patients. The study found that all participants were free of cancer at the end and quality of life was similar in both treatment arms at 12 months. However, recruitment for such a clinical trial was challenging, considering the risks of undertreatment and overtreatment in HRNMIBC patients.
Article
Urology & Nephrology
Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy, Masha Kocherginsky, Suchitra Swaminathan, Sabah S. Munir, Robert S. Svatek, Timothy Kuzel, Joshua J. Meeks
Summary: Intravesical pembrolizumab combined with BCG is a safe and feasible treatment option for bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer, capable of eliciting strong immune responses.
Article
Oncology
Michael Chandra, Roger Li, Anil Parwani, William E. Carson III, Kamal Pohar, Debasish Sundi
Summary: Enrollment criteria for patients with BCG unresponsive bladder cancer are highly variable, with over half of evaluated trials not meeting stringent criteria for this disease state. This restricts patient access to novel agents and hinders comparisons across different treatments for bladder cancer.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Review
Oncology
Susanne Deininger, Peter Toerzsoek, Michael Mitterberger, Maximilian Pallauf, David Oswald, Christian Deininger, Lukas Lusuardi
Summary: In non-muscle-invasive bladder cancer, immune-modulating therapies and oncolytic virus instillations show good efficacy without significant systemic adverse events. Recombinant BCG and recombinant pox-viral vector vaccines need further investigation, and interleukin mediating therapies are currently being studied.
Article
Urology & Nephrology
Mathieu Roumiguie, Eva Comperat, Leonor Chaltiel, Francois Xavier Nouhaud, Gregory Verhoest, Alexandra Masson-Lecomte, Pierre Colin, Francois Audenet, Nadine Houede, Stephane Larre, Evanguelos Xylinas, Serge Brunelle, Jeanne Piana-Thomassin, Juliette Cotte, Geraldine Pignot, Yann Neuzillet, Morgan Roupret
Summary: This study found an association between PD-L1 expression and BCG failure in HR-NMIBC, but PD-L1 + status was not a prognostic factor in the response to BCG. The results highlight the key role played by the immune cells in the microenvironment in BCG treatment, suggesting the rationale for combining BCG and PD-L1/PD-1 antibodies in early bladder cancer.
WORLD JOURNAL OF UROLOGY
(2021)
Editorial Material
Oncology
L. Paz-Ares, M. E. R. O'Brien, M. Mauer, U. Dafni, K. Oselin, L. Havel, E. Esteban Gonzalez, D. Isla, A. Martinez-Marti, M. Faehling, M. Tsuboi, J-s. Lee, K. Nakagawa, J. Yang, S. M. Keller, N. Jha, S. I. Marreaud, R. A. Stahel, S. Peters, B. Besse
Summary: This study evaluated the efficacy of adjuvant pembrolizumab compared to placebo in patients with completely resected early-stage non-small cell lung cancer. The results showed that adjuvant pembrolizumab significantly improved disease-free survival in the overall population, but did not reach statistical significance in the PD-L1 expression >= 50% population. Adverse events were more common in the pembrolizumab group compared to the placebo group.
ANNALS OF ONCOLOGY
(2022)
Article
Medicine, General & Internal
Ryohta Nakamura, Go Hasegawa, Yohei Ikeda, Noboru Hara, Tsutomu Nishiyama
Summary: This is a case report of an 82-year-old male patient diagnosed with synchronous non-muscle-invasive bladder cancer and left lower ureteral carcinoma. The patient underwent transurethral resection of the bladder tumor and total left nephroureterectomy after preoperative chemotherapy. Histopathological findings revealed positive-margin carcinoma in situ. Despite Bacille Calmette-Guerin intravesical infusion therapy and recurrence of non-muscle-invasive bladder cancer, complete remission was achieved after pembrolizumab therapy.
SAGE OPEN MEDICAL CASE REPORTS
(2023)
Article
Urology & Nephrology
Girish S. Kulkarni, Lothar Lilge, Michael Nesbitt, Roger J. Dumoulin-White, Arkady Mandel, Michael A. S. Jewett
Summary: Photodynamic therapy with TLD-1433 appears to be safe and effective for the treatment of bacillus Calmette-Guerin (BCG)-unresponsive bladder cancer.
EUROPEAN UROLOGY OPEN SCIENCE
(2022)
